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Abstract
Background: There is evidence for a relevant role of inflammation in the pathogenesis of Parkinson’s disease (PD).
Mutations in the LRRK2 gene represent the most frequent genetic cause for autosomal dominant PD. LRRK2 is
highly expressed in macrophages and microglia suggesting an involvement in inflammatory pathways. The
objectives are to test (1) whether idiopathic PD and LRRK2-associated PD share common inflammatory pathways
or present distinct profiles and (2) whether non-manifesting LRRK2 mutation carriers present with similar aspects of
inflammatory profiles as seen in PD-affected patients.
Methods: We assessed serum profiles of 23 immune-associated markers and the brain-derived neurotrophic factor
in 534 individuals from the MJFF LRRK2 consortium.
Results: A large proportion of inflammatory markers were gender-dependent. Both PD-affected cohorts showed
increased levels of the pro-inflammatory marker fatty-acid-binding protein. Additionally, idiopathic PD but not
LRRK2-associated PD patients showed increased levels of the pro-inflammatory marker interleukin-12-p40 as
well as the anti-inflammatory species interleukin-10, brain-derived neurotrophic factor, and stem cell factor.
Non-manifesting LRRK2 mutation carriers including those with prodromal characteristics of PD presented with
control-like inflammatory profiles.
Conclusions: Concomitant inflammation seems to be associated with idiopathic and LRRK2-associated PD.
Identifying PD patients in whom inflammatory processes play a major role in their pathophysiology might offer a
new therapeutic window at least for a subgroup of patients. Since non-manifesting LRRK2 mutation carriers with
symptoms of the prodromal phase of PD did not show inflammatory profiles, activation of the immune system
seems not an early event in the disease cascade.
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Background
There is increasing evidence coming from post-mortem
and biomarker analyses as well as genetic studies that in-
flammation is relevantly involved in the pathogenesis of
Parkinson’s disease (PD) (reviewed in [1–8]). Although
levels of cytokines and chemokines are highly variable, a
substantial proportion of PD patients can show elevated
levels of these proteins in serum and CSF (reviewed in
[2]). This increase indicates an activation of the innate
immune system with involvement of astrocytes and acti-
vation of microglia (reviewed in [1, 4]). Subtypes of
astrocytes have recently been shown to effectively endo-
cytose α-synuclein (asyn) species secreted from neurons
and to produce glial inclusions and inflammatory re-
sponses [9].
Mutations in the gene for leucine-rich repeat kinase
(LRRK2) represent the most frequent genetic cause
associated with autosomal dominant PD. In general, the
clinical phenotype of PD patients with LRRK2 mutation
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(PDLRRK2) resembles late-onset idiopathic PD (IPD) with
a good response to levodopa treatment. However, with
respect to non-motor symptoms such as dementia and
olfactory dysfunction, the clinical course in patients car-
rying the most common LRRK2 mutation (p.G2019S)
appears to be more benign than in IPD [10, 11]. There is
increasing evidence for the involvement of LRRK2 in in-
flammatory pathways, linking PDLRRK2 to the immune
system [3, 4]. LRRK2 is highly expressed in monocytes,
macrophages, and microglia, and exposure to bacterial
lipopolysaccharides (LPS) results in an up-regulation of
LRRK2 protein as well as impaired autophagy in macro-
phages [4, 12]. Following this line, one could speculate
that PDLRRK2 might be associated with distinct inflam-
matory cascades.
At present, it is not clear (1) whether idiopathic
and LRRK2-associated PD share common inflamma-
tory pathways or present with distinct profiles and (2)
whether non-manifesting LRRK2 mutation carriers
(NMCLRRK2) present with similar aspects of inflamma-
tory profiles as seen in PD-affected patients indicating
an involvement of the immune system in earliest neu-
rodegenerative processes. To evaluate these questions
in this exploratory study, we applied an extensive bat-
tery of 27 immune-associated serum markers as well
as the neurotrophin BDNF (which is directly secreted
by activated monocytes in inflammatory brain lesions
and promotes neuronal survival in vitro [13]) in a
large multicenter cohort of the MJFF LRRK2 consor-
tium consisting of 534 individuals.
Methods
Centers and participants
In 2008, the Michael J. Fox Foundation established an
international consortium to investigate the role of
LRRK2 in Parkinson’s disease (www.michaeljfox.org/
page.html?lrrk2-cohort-consortium). The consortium
brought together leading groups focusing on genetic
forms of PD from nine countries across four continents
(Canada, China, France, Germany, Israel, Norway, Spain,
Tunisia, and the USA).
In total, clinical data and serum samples of 534 indi-
viduals from Canada, France, Germany, Norway, Spain,
and the USA grouped into 4 cohorts were included in
these cross-sectional analyses: (1) 144 IPD patients con-
trolled to have no pathogenic mutation in the LRRK2
gene, (2) 142 PDLRRK2, (3) 115 NMCLRRK2, and (4) 133
healthy control individuals controlled to have no patho-
genic LRRK2 mutation (CON); please see Additional file
1: Table S1 for the type of mutations and their distribu-
tion among the LRRK2 cohorts.
Since PDLRRK2 is characterized by reduced penetrance
and not all NMCLRRK2 will develop PD, we defined—in
accordance with the new MDS research criteria for
prodromal PD [14]—a “prodromal subgroup” of
NMCLRRK2 individuals who may have a particularly
high risk of conversion by carrying a genetic risk
factor (LRRK2 mutation) and additionally fulfilling at
least two of the following prodromal criteria: mild
motor impairment (MDS-UPDRS-III > 6), REM sleep
behavior disorder (RBD Questionnaire ≥ 5), autonomic
dysfunction (SCOPA-AUT ≥ 9), or hyposmia (age-related
UPSIT cut-off [15]). Thirty-three NMCLRRK2 individuals
met these criteria and fell into this prodromal subgroup
(Tables 1, 2, 3, and 4).
Clinical investigations
The consortium followed standardized data acquisition
protocols to ensure that tests conducted at multiple sites
can be pooled. Besides demographics such as gender, age,
age at onset, and disease duration, the following clinical
parameters were of interest and analyzed in the present
study. Diagnosis of Parkinson’s disease was defined ac-
cording to the UK Brain Bank Criteria with the exception
that a positive family history for PD was not considered
an exclusion criterion [16]. Severity of motor symptoms
was assessed using part III of the MDS-Unified Parkin-
son’s disease Rating Scale (MDS-UPDRS-III) [17]. Stage of
disease was categorized according to the modified Hoehn
and Yahr Scale (H&Y) [18]. Cognitive function was tested
by the Montreal Cognitive Assessment (MoCA). A cut-off
of ≤26 out of 30 points was set to indicate cognitive
impairment [19]. A cut-off of ≥5 points in the REM Sleep
Behavior Disorder Screening Questionnaire (RBD Ques-
tionnaire) was interpreted as presence of RBD [20]. The
Epworth Sleepiness Scale (ESS) was used to assess exces-
sive daytime sleepiness [21] and the SCOPA-AUT to as-
sess autonomic dysfunction [22].
Biomaterial and analyses of immune-associated markers
in serum
Serum samples were collected after overnight fasting be-
tween 8.00 and 11.00 am, prepared and stored according
to standardized operating procedures as defined by the
MJFF consortium. Serum was centrifuged at 2000 g, 4 °C
for 10 min and stored at −80 °C within 60 min after col-
lection. Levels of 28 immune-associated markers were
measured as follows: samples were thawed at room
temperature, vortexed, spun at 18.000 × g for 1 min and
pipetted into a master microtiter plate for multiplexed
immunoassay. The kit components of the multiplexed
immunoassay were kindly provided by Myriad RBM,
Austin, TX, USA (http://rbm.myriad.com). After dilution
with assay diluents in a manner of 1:5, an aliquot of 10-
μl diluted serum was introduced into one of the capture
microsphere multiplexes followed by incubation at room
temperature for 1 h. Reporter antibodies were added
followed by incubation for an additional hour at room
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Table 1 Overview of demographic and clinical data as well as inter-group comparisons for the cohorts IPD, PDLRRK2 and CON stratified by gender
Female
N = 211
Male
N = 208
Female Male
IPD
N = 49
PDLRRK2
N = 73
CON
N = 89
IPD
N = 95
PDLRRK2
N = 69
CON
N = 44
p value
IPD
PDLRRK2
CON
p value
Post hoc
IPD
CON
p value
Post hoc
PDLRRK2
CON
p value
Post hoc
IPD
PDLRRK2
p value
IPD
PDLRRK2
CON
p value
Post hoc
IPD
CON
p value
Post hoc
PDLRRK2
CON
p value
Post hoc
IPD
PDLRRK2
Age
Years
68
46–83
67
35–89
57
18–83
69
46–80
65
36–88
58
28–83
0.001 0.001 0.001 0.999 0.001 0.001 0.012 0.204
Age at onset
Years
60
39–77
59
29–76
61
39–75
54
23–82
0.280 0.001
Disease duration
Years
7
1–20
10
1–25
7
1–21
11
1–34
0.003 0.001
UPDRS-III 26
6–64
18
2–82
0
0–9
28
9–61
19
1–70
0
0–8
0.001 0.001 0.001 0.379 0.001 0.001 0.001 0.001
HY 2
1–4
2
1–5
2
1–4
2
1–5
0.544 0.889
MoCA 27
11–30
25
6–30
27
17–30
27
13–30
24
5–30
27
17–30
0.001 0.999 0.001 0.014 0.001 0.999 0.002 0.001
RBD Questionnaire 3
0–11
3
0–11
1
0–13
4
0–13
3
0–12
1
0–11
0.001 0.001 0.001 0.941 0.001 0.001 0.017 0.009
ESS 9
1–18
6
0–24
6
0–15
10
0–23
8
0–24
6
0–14
0.002 0.002 0.999 0.024 0.001 0.001 0.246 0.057
SCOPA-AUT 15
2–36
15
0–45
7
0–41
13
0–40
12
0–51
6
0–30
0.001 0.001 0.001 0.999 0.001 0.001 0.001 0.999
Regular anti-inflammatory medication
(% of individuals)
12.2 10.3 1.2 10.5 3.1 0.0 0.022 0.010 0.023 0.772 0.032 0.033 0.522 0.125
Data are presented as median with range. p values reflect results from Kruskal-Wallis test and, in case of significant differences between the three cohorts, pair-wise post hoc Dunn Test including correction for multiple
comparisons. Statistical analysis for the intake of anti-inflammatory medication was done using chi-square test
IPD patients with idiopathic Parkinson’s disease, PDLRRK2 patients with Parkinson’s disease carrying a LRRK2 mutation, NMCLRRK2 non-manifesting LRRK2 mutation carriers, CON healthy control individuals, ESS Epworth
Sleepiness Scale, HY Hoehn and Yahr Scale, LEDD levodopa-equivalent daily dosage, MoCA Montreal Cognitive Assessment, RBD REM sleep behavior disorder, UPDRS-III Unified Parkinson’s disease Rating Scale
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Table 2 Overview of levels of inflammatory-related and neurotrophic markers as well as inter-group comparisons for the cohorts IPD, PDLRRK2, and CON stratified by gender
Female
N = 211
Male
N = 208
Female Male
Serum marker IPD
N = 49
PDLRRK2
N = 73
CON
N = 89
IPD
N = 95
PDLRRK2
N = 69
CON
N = 44
p value
IPD
PDLRRK2
CON
p value
Post
hoc
IPD
CON
p value
Post
hoc
PDLRRK2
CON
p value
Post
hoc
IPD
PDLRRK2
p value
IPD
PDLRRK2
CON
p value
Post
hoc
IPD
CON
p value
Post
hoc
PDLRRK2
CON
p value
Post
hoc
IPD
PDLRRK2
Alpha fetoprotein
ng/ml
0.97
0.09–6.20
0.81
0.12–4.07
0.76
0.07–6.94
1.17
0.14–7.17
0.93
0.12–14.10
0.95
0.33–3.52
0.004 0.008 0.017 0.014 0.034 0.070 0.849 0.032
BDNF
(Brain-derived neurotrophic
factor)
ng/ml
27.40
15.50–40.60
18.90
3.85–55.40
19.70
2.92–41.70
25.50
10.60–56.30
15.60
1.52–37.20
17.05
2.88–45.10
<0.001 <0.001 0.053 <0.001 <0.001 <0.001 0.311 <0.001
ENA-78
(Epithelial-derived neutrophil-
activating peptide 78)
ng/ml
2.08
0.82–6.15
1.91
0.56–8.36
2.03
0.48–7.70
1.62
0.48–4.61
1.43
0.36–5.08
1.54
0.19–4.77
0.403 0.710 0.499 0.307 0.465 0.439 0.016 0.766
FABP
(Fatty-acid-binding protein)
ng/ml
4.97
2.24–81.10
3.71
0.40–26.70
2.87
0.97–12.00
5.91
1.45–22.20
4.44
1.37–18.90
4.04
1.44–11.50
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.006 0.002
GH
(Growth hormone)
ng/ml
1.39
0.11–14.40
2.47
0.08–26.50
1.61
0.11–29.60
0.79
0.04–14.90
0.87
0.08–30.80
0.36
0.07–24.50
0.145 0.326 0.415 0.117 0.004 0.083 0.005 0.030
ICAM-1
(Intercellular adhesion
molecule 1)
ng/ml
152.62
65.70–224.00
161.00
73.50–262.00
160.00
80.00–288.00
149.00
71.60–273.00
150.00
51.60–246.00
150.50
83.40–
232.00
0.340 0.544 0.722 0.018 0.251 0.183 0.529 0.267
IL-1-beta
pg/ml
2.18
1.02–4.97
1.83
0.29–4.53
1.84
0.56–4.10
2.57
1.11–17.10
2.38
0.71–5.22
2.17
1.02–3.30
0.052 0.018 0.726 0.239 0.012 0.019 0.179 0.033
IL-4
pg/ml
16.80
8.20–33.20
15.10
5.57–27.00
15.10
6.73–31.50
15.90
5.16–41.20
13.20
4.43–27.10
13.10
5.02–27.00
0.097 0.409 0.083 0.095 0.024 0.070 0.671 0.030
IL-6
pg/ml
4.36
1.67–20.30
4.26
1.27–16.30
3.65
1.27–99.10
5.29
1.67–13.90
5.63
2.00–13.70
4.71
2.17–9.57
0.008 0.017 0.053 0.020 0.033 0.346 0.002 0.254
IL-8
pg/ml
9.72
2.85–38.10
12.90
3.17–60.70
11.60
3.60–60.30
10.70
2.94–771.00
12.30
2.93–209.00
10.75
2.65–77.50
0.052 0.025 0.242 0.232 0.332 0.428 0.145 0.054
IL-10
pg/ml
4.68
1.72–36.10
3.72
1.78–19.20
3.26
1.78–21.80
5.09
2.55–36.90
3.29
1.78–13.80
3.26
1.78–7.59
0.001 <0.001 0.392 0.032 <0.001 <0.001 0.488 <0.001
IL-12-p40
ng/ml
0.29
0.12–0.71
0.21
0.10–0.49
0.24
0.07–0.69
0.25
0.07–0.88
0.22
0.07–0.62
0.16
0.07–0.36
0.007 0.004 0.228 0.016 <0.001 <0.001 0.015 0.059
IL-16
pg/ml
532.00
152.00–
1000.00
543.00
237.00–
1080.00
551.00
239.00–
1370.00
522.00
224.00–
1580.00
497.00
232.00–
1310.00
520.00
268.00–
760.00
0.537 0.265 0.535 0.663 0.611 0.851 0.603 0.403
IL-18
pg/ml
282.00 272.00 282.00 304.00 312.00 306.00 0.521 0.390 0.725 0.362 0.094 0.812 0.040 0.020
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Table 2 Overview of levels of inflammatory-related and neurotrophic markers as well as inter-group comparisons for the cohorts IPD, PDLRRK2, and CON stratified by gender
(Continued)
147.00–
546.00
101.00–
752.00
140.00–
3360.00
137.00–
925.00
133.00–
771.00
141.00–
681.00
Leptin
ng/ml
17.50
4.83–56.20
17.80
0.66–113.00
15.70
2.10–123.00
6.59
0.69–46.00
6.74
0.63–32.40
7.06
1.14–32.50
0.934 0.460 0.624 0.951 0.534 0.781 0.162 0.631
MCP-1
(Monocyte chemotactic
protein 1)
pg/ml
396.00
177.00–
941.00
366.00
152.00–
1190.00
342.00
113.00–
844.00
448.00
21.90–872.00
333.00
99.90–802.00
323.50
120.00–
916.00
0.511 0.268 0.922 0.136 0.066 0.006 0.389 0.115
MDC
(Macrophage-derived
chemokine)
pg/ml
425.00
292.00–
676.00
516.00
125.00–
964.00
474.00
93.80–
1800.00
401.00
171.00–
838.00
407.00
146.00–
3860.00
483.00
188.00–
950.00
0.113 0.289 0.286 0.014 0.014 0.017 0.381 0.036
MIP-1-beta
(Macrophage inflammatory
protein-1-beta)
pg/ml
251.00
70.50–
1160.00
217.00
18.40–588.00
215.00
62.20–955.00
237.00
29.70–737.00
207.00
75.90–
1530.00
208.00
69.40–
2520.00
0.034 0.011 0.097 0.264 0.762 0.536 0.491 0.189
MMP-3
(Matrix-metallo-proteinase-3)
ng/ml
14.80
4.42–37.10
13.50
6.31–120.00
12.30
6.08–92.90
23.00
7.28–59.90
24.00
8.01–48.40
23.55
9.61–53.80
0.013 0.052 0.029 0.057 0.594 0.891 0.703 0.283
MMP-9
(Matrix-metallo-proteinase-9)
ng/ml
16.80
6.80–28.00
20.90
9.28–46.20
19.60
12.60–61.60
21.20
12.10–42.30
27.00
15.60–121.00
25.40
16.10–37.80
<0.000 <0.001 0.100 <0.001 <0.001 0.222 0.058 <0.001
SCF
(Stem cell factor)
pg/ml
319.00
169.00–
535.00
269.00
78.30–635.00
277.00
117.00–
614.00
293.00
154.00–
514.00
251.00
81.90–587.00
279.00
127.00–
494.00
<0.001 <0.001 0.016 0.009 0.001 0.004 0.344 <0.001
TF
(Tissue factor)
ng/ml
0.28
0.08–0.72
0.25
0.12–0.67
0.24
0.07–0.53
0.43
0.08–23.80
0.32
0.13–0.74
0.30
0.15–0.43
0.064 0.231 0.002 0.833 0.011 0.057 0.187 0.102
TNF-alpha
(Tumor necrosis factor alpha)
pg/ml
58.70
11.70–110.00
60.00
21.20–129.00
60.00
27.60–110.00
76.50
39.20–187.00
73.30
30.30–143.00
69.30
49.80–
105.00
0.666 0.294 0.925 0.427 0.200 0.299 0.161 0.296
TPO
(Thrombopoietin)
pg/ml
2.67
1.75–3.55
2.07
0.19–3.76
2.37
0.56–4.48
2.54
1.62–3.68
1.98
0.31–4.08
2.25
0.59–3.64
<0.001 0.002 0.042 0.001 <0.001 <0.001 0.069 <0.001
Data are presented as median with range. p values reflect results from inter-group comparisons between IPD, PDLRRK2, and CON using multivariate variance analysis including age, regular intake of anti-inflammatory
medication, and study site as co-variates. Correction for multiple testing for the number of groups that have been compared (n = 3 for IPD, PDLRRK2, CON = p < 0.016) was done according to Bonferroni and statistical
significance was defined as p < 0.016. In case of significant differences between the three cohorts, we calculated pair-wise post hoc comparison including age, regular intake of anti-inflammatory medication, and study
site as co-variates; and in the case of comparison between IPD and PDLRRK2, also disease duration was introduced as co-variate
IPD patients with idiopathic Parkinson’s disease, PDLRRK2 patients with Parkinson’s disease carrying a LRRK2 mutation, CON healthy control individuals
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temperature. Streptavidin-phycoerythrin solution was
added for development and incubated for 1 h at room
temperature. For control purposes, calibrators and con-
trols were included on each microtiter plate. Standard
curve, control, and sample QC were performed to en-
sure proper assay performance (please see Additional file
1: Table S3 for details on LLD, LLOQ, and average con-
centrations as well as intra- and inter-assay CVs). Sam-
ples were tested in singles. Analysis was performed using
the Luminex 100/200 instrument and data were inter-
preted using the software developed and provided by
Myriad RBM.
The following 4 serum markers were excluded from
analysis due to missing values in >5 % of study partici-
pants: IL-1α, IL-7, IL-13, and IL-15. Of the remaining,
approximately 1 % of the overall data were missing
values, which were replaced by the overall group mean
of the respective parameter. A total of 23 immune-
associated serum markers as well as BDNF were in-
cluded in the analyses. For a list of all assessed markers,
we refer to Tables 2 and 4.
Statistics
Statistical analysis was performed using SPSS 22.0 soft-
ware for Windows SPSS (Inc., Chicago, IL, III, USA). Di-
chotomous data were analyzed using the chi-square test.
1. Multivariate linear regression analyses stratified by
cohort were used to evaluate independent
associations of gender, age, disease duration, intake
of anti-inflammatory medication, and clinical char-
acteristics with levels of immune markers.
2. To evaluate PD disease status-specific characteristics,
we performed inter-group comparisons of demo-
graphic, clinical, and immune marker levels between
the two PD cohorts and healthy control individuals
(IPD, PDLRRK2, CON). Due to skewed data, non-
parametric testing using Kruskal-Wallis test was per-
formed for the comparison of demographic and clinical
data. In case of significant differences in the Kruskal-
Wallis test, pair-wise post hoc Dunn test including
correction for multiple testing was applied. Levels of
immune markers were first normalized by log trans-
formation before inter-group comparisons using multi-
variate variance analyses corrected for age, intake of
anti-inflammatory medication, and study site were
done. In case of significant differences in the multivari-
ate variance analysis, pair-wise post hoc comparisons
also corrected for age, disease duration (comparison of
the two PD cohorts), intake of anti-inflammatory medi-
cation, and study site were applied. Correction for mul-
tiple testing for the number of groups that have been
compared (n = 3 for IPD, PDLRRK2, CON= p < 0.016)
was done according to Bonferroni. The pair-wise post
hoc comparison between the two PD cohorts (IPD,
PDLRRK2) further allowed evaluating LRRK2-specific
effects in the PD patients.
3. Discriminant analysis in IPD, PDLRRK2, and CON
including all assessed serum markers was performed to
test whether specific immune profiles could
Table 3 Overview of demographic and clinical data as well as inter-group comparisons for the cohorts NMCLRRK2 and CON stratified
by gender
Female
N = 152
Male
N = 96
Female Male
NMCLRRK2
N = 63
CON
N = 89
NMCLRRK2
N = 52
CON
N = 44
p value
NMCLRRK2
CON
p value
NMCLRRK2
CON
Age
Years
51
23–84
57
18–83
54
27–82
58
28–83
0.087 0.110
UPDRS-III 0
0–13
0
0–9
0
0–15
0
0–8
0.021 0.542
MoCA 28
18–30
27
17–30
27
18–30
27
17–30
0.756 0.809
RBD Questionnaire 1
0–9
1
0–13
2
0–9
1
0–11
0.396 0.943
ESS 6
0–15
6
0–15
5
0–15
6
0–14
0.948 0.399
SCOPA-AUT 8
1–33
7
0–41
7
0–39
6
0–30
0.221 0.729
Regular anti-inflammatory medication
(% of individuals)
3.7 1.2 4.6 0.0 0.561 0.495
Data are presented as median with range. p values reflect results from Mann–Whitney test. The intake of anti-inflammatory medication is given as % of individuals
from the respective cohort; statistical analysis was done using chi-square test
NMCLRRK2 non-manifesting LRRK2 mutation carriers, CON healthy control individuals, ESS Epworth Sleepiness Scale, HY Hoehn and Yahr Scale, LEDD levodopa-equivalent
daily dosage, MoCA Montreal Cognitive Assessment, RBD REM sleep behavior disorder, UPDRS-III Unified Parkinson’s disease Rating Scale
Brockmann et al. Journal of Neuroinflammation  (2016) 13:122 Page 6 of 13
Table 4 Overview of levels of inflammatory-related and neurotrophic markers as well as inter-group comparisons for the cohorts NMCLRRK2 (total and prodromal subgroup) and
CON stratified by gender
Female
N = 152
Male
N = 96
Female Male
Serum Marker NMCLRRK2
N = 63
NMCLRRK2
Prodromal
N = 18
CON
N = 89
NMCLRRK2
N = 52
NMCLRRK2
Prodromal
N = 15
CON
N = 44
p value
NMCLRRK2
CON
p value
NMCLRRK2
Prodromal
CON
p value
NMCLRRK2
CON
p value
NMCLRRK2
Prodromal
CON
Alpha fetoprotein
ng/ml
0.59
0.06–3.53
0.58
0.19–2.28
0.76
0.07–6.94
0.89
0.14–2.47
0.93
0.31–2.47
0.95
0.33–3.52
0.004 0.051 0.068 0.281
BDNF
(Brain-derived neurotrophic factor)
ng/ml
17.50
3.30–41.70
26.20
3.85–41.70
19.70
2.92–41.70
13.00
1.40–40.50
6.98
1.74–36.60
17.05
2.88–45.10
0.376 0.258 0.026 0.128
ENA-78
(Epithelial-derived neutrophil-activating
peptide 78)
ng/ml
2.14
0.38–5.77
2.26
0.38–5.76
2.03
0.48–7.70
1.63
0.46–5.98
1.71
0.46–3.75
1.54
0.19–4.77
0.610 0.811 0.016 0.203
FABP
(Fatty-acid-binding protein)
ng/ml
2.87
0.88–14.40
3.03
1.62–7.99
2.87
0.97–12.00
3.71
2.05–17.80
3.80
2.44–17.80
4.04
1.44–11.50
<0.001 <0.001 <0.001 0.096
GH
(Growth hormone)
ng/ml
2.18
0.08–35.60
3.16
0.08–30.30
1.61
0.11–29.60
0.35
0.06–6.28
0.36
0.06–1.37
0.34
0.07–24.50
0.109 0.266 0.175 0.270
ICAM-1
(Intercellular adhesion molecule 1)
ng/ml
156.00
103.00–317.00
157.50
121.00–224.00
160.00
80.00–288.00
154.50
99.10–329.00
155.00
99.10–329.00
150.50
83.40–232.00
0.839 0.930 0.085 0.632
IL-1-beta
pg/ml
1.76
0.71–4.41
2.07
0.94–4.41
1.84
0.56–4.10
2.22
0.78–4.68
2.46
0.78–3.67
2.17
1.02–3.30
0.427 0.072 0.471 0.158
IL-4
pg/ml
15.90
4.89–30.00
15.80
9.01–26.80
15.10
6.73–31.50
13.10
5.02–23.60
14.82
8.19–20.90
14.00
5.02–27.00
0.562 0.458 0.333 0.692
IL-6
pg/ml
3.65
1.05–10.60
3.71
2.11–8.77
3.65
1.27–99.10
4.42
2.50–17.50
4.87
2.50–10.30
4.71
2.17–9.57
0.062 0.039 0.246 0.223
IL-8
pg/ml
10.70
4.89–30.00
10.85
3.17–84.00
11.60
3.60–60.30
10.30
2.36–39.20
10.50
6.53–39.20
10.75
2.65–77.50
<0.001 0.039 0.029 0.288
IL-10
pg/ml
3.57
1.78–32.80
3.61
1.80–9.69
3.26
1.78–7.70
3.44
1.78–9.96
3.49
1.78–9.96
3.26
1.78–7.59
0.910 0.809 0.820 0.932
IL-12-p40
ng/ml
0.24
0.07–0.77
0.24
0.07–0.77
0.24
0.07–0.69
0.19
0.08–0.38
0.22
0.09–0.38
0.16
0.07–0.36
0.010 0.001 0.294 0.432
IL-16
pg/ml
497.00
177.00–752.00
532.50
342.00–735.00
551.00
239.00–1370.00
524.00
261.00–1060.00
549.00
419.00–815.00
520.00
268.00–760.00
0.007 0.197 0.100 0.281
IL-18
pg/ml
288.00
110.00–15000.00
290.00
152.00–440.00
282.00
140.00–3360.00
313.00
165.00–872.00
333.00
186.00–872.00
306.00
141.00–681.00
0.551 0.828 0.083 0.084
Leptin
ng/ml
17.10
1.90–90.60
24.25
7.16–44.70
15.70
2.10–123.00
7.03
1.48–38.40
9.90
3.60–31.90
7.06
1.14–32.50
0.674 0.035 0.314 0.475
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Table 4 Overview of levels of inflammatory-related and neurotrophic markers as well as inter-group comparisons for the cohorts NMCLRRK2 (total and prodromal subgroup) and
CON stratified by gender (Continued)
MCP-1
(Monocyte chemotactic protein 1)
pg/ml
333.00
40.80–854.00
325.50
199.00–635.00
342.00
113.00–844.00
329.50
12.20–740.00
292.00
12.20–667.00
323.50
120.00–916.00
0.246 0.631 0.148 0.290
MDC
(Macrophage-derived chemokine)
pg/ml
452.00
216.00–981.00
539.50
216.00–981.00
474.00
93.80–1800.00
464.00
217.00–855.00
423.00
261.00–774.00
483.00
188.00–950.00
0.514 0.504 0.249 0.692
MIP-1-beta
(Macrophage inflammatory
protein-1-beta)
pg/ml
183.00
61.50–720.00
240.00
61.50–436.00
215.00
62.20–955.00
167.00
77.20–736.00
220.00
77.20–736.00
208.00
69.40–2520.00
0.607 0.302 0.240 0.604
MMP-3
(Matrix-metallo-proteinase-3)
ng/ml
10.70
4.04–66.60
12.70
6.32–66.60
12.30
6.08–92.90
21.35
11.30–46.80
21.00
11.90–45.20
23.55
9.61–53.80
<0.001 0.055 0.418 0.600
MMP-9
(Matrix-metallo-proteinase-9)
ng/ml
20.40
10.80–40.90
22.45
11.90–40.90
19.60
12.60–61.60
25.70
16.10–36.10
25.30
16.10–36.10
25.40
16.10–37.80
0.009 0.007 0.762 0.931
SCF
(Stem cell factor)
pg/ml
264.00
154.00–520.00
263.00
193.00–404.00
277.00
117.00–614.00
280.00
145.00–635.00
299.00
190.00–458.00
279.00
127.00–494.00
0.013 0.037 0.076 0.166
TF
(Tissue factor)
ng/ml
0.24
0.12–0.57
0.26
0.15–0.57
0.24
0.07–0.53
0.29
0.13–1.67
0.32
0.16–0.48
0.30
0.15–0.43
0.004 0.004 0.514 0.464
TNF-alpha
(Tumor necrosis factor alpha)
pg/ml
54.30
27.60–106.00
55.75
41.60–106.00
60.00
27.60–110.00
74.60
33.00–103.00
78.30
38.40–98.60
69.30
49.80–105.00
0.752 0.652 0.149 0.262
TPO
(Thrombopoetin)
pg/ml
2.08
0.19–3.86
2.24
0.22–3.49
2.37
0.56–4.48
1.62
0.55–4.18
2.05
0.55–3.87
2.37
0.59–3.64
0.175 0.204 0.082 0.115
Data are presented as median with range. p values reflect results from inter-group comparisons between NMCLRRK2 and CON using multivariate variance analysis including age, regular intake of anti-inflammatory medi-
cation, and study site as co-variates. Correction for multiple testing for the number of groups that have been compared (n = 2 for NMCLRRK2, CON = p < 0.025) was done according to Bonferroni and statistical signifi-
cance was defined as p < 0.025
NMCLRRK2 non-manifesting LRRK2 mutation carriers, CON healthy control individuals
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discriminate between disease status and genotype and
thereby correctly classify individuals to the respective
cohort based on the immune marker profile.
Discriminant analysis is similar to linear regression by
predicting an outcome. The difference between both
methods is the classification of the dependent variable
which should be categorical when using discriminant
analysis (in our case, the three cohorts) as opposed to
linear regression where the dependent variable is an
interval variable, thereby impeding this method for our
analysis. The variable “cohort” was introduced as
dependent variable whereas all immune markers were
entered at once without prior selection (to ensure an
unbiased analysis) as predictors (independent
variables). The discriminant analysis weights the
effect of all immune markers in order to identify
and combine the most important ones which are
referred to as discriminant score.
4. To test whether NMCLRRK2 present with similar
aspects of inflammatory profiles as seen in the PD-
affected cohorts, we performed inter-group compari-
sons of demographic, clinical and immune markers
between NMCLRRK2 and CON. Due to skewed data,
non-parametric testing using Mann–Whitney test
was performed for the comparison of demographic
and clinical data. Levels of immune markers were
first normalized by log transformation before inter-
group comparisons using multivariate variance
analyses corrected for age were done. Correction
for multiple testing for the number of groups that
have been compared (n = 2 for NMCLRRK2 CON =
p < 0.025) was done according to Bonferroni.
Since regression analysis revealed a significant im-
pact of gender on the immune marker levels and gen-
der was distributed differently across our cohorts, all
analyses outlined in this section were done separately
stratified by gender.
Standard protocol approvals, registrations, and patient
consents
The study was approved by the respective local ethics
committees of the participating centers. All participants
gave written informed consent.
Results
Clinical and demographic characteristics of the cohorts
IPD, PDLRRK2, and CON are shown in Table 1; the re-
spective data for NMCLRRK2 are given in Table 3.
1. Multivariate linear regression analyses stratified by
cohort revealed a relevant impact of gender on levels of
immune markers. While females had significantly
higher levels of ENA-78, GH, IL-4, IL-12-p40, and
leptin, males showed higher levels of FABP, IL-1-beta,
IL-6, MMP-3, MMP-9, TF, and TNF-alpha. Moreover,
discriminant analysis revealed a clear separation be-
tween genders based on the immune marker profile in
the overall cohort of 534 individuals with a correct
classification to the respective gender of 87.8 %. For
details, see Additional file 1: Table S2 and Additional
file 2: Figure S1.
2. Detailed descriptive data and results of inter-group
comparisons including post hoc pair-wise compari-
son of levels of immune markers between IPD,
PDLRRK2, and CON are given in Table 2. Compared
to CON, females and males of both PD cohorts had
significantly higher levels of the pro-inflammatory
marker FABP. Moreover, IPD but not PDLRRK2 had
significantly higher levels of the pro-inflammatory
marker IL-12-p40 as well as of the anti-inflammatory
marker IL-10, the neurotrophic factor BDNF, and the
survival factor SCF compared to CON. Levels of
MMP-9 were lowest in IPD compared to PDLRRK2.
3. Discriminant analysis in IPD, PDLRRK2, and CON
including all assessed serum markers revealed FABP
(structure matrix coefficient: female = 0.273, male =
0.272), IL-1-beta (structure matrix coefficient: female =
0.220, male = 0.240), IL-12-p40 (structure matrix coef-
ficient: female = 0.230, male = 0.435), MMP-9 (struc-
ture matrix coefficient: female = −0.263, male = 0.476),
TPO (structure matrix coefficient: female = −0.398,
male = 0.412), and BDNF (structure matrix coefficient:
female = 0.337, male = 0.544) as the most important
factors for discrimination. Overall, 69.7 % of the female
and 71.2 % of the male individuals could be correctly
classified to the respective cohort based on the immune
profile.
4. Detailed descriptive data and results of inter-group
comparisons of levels of immune markers between
NMCLRRK2 and CON are given in Table 4. Female
NMCLRRK2 who were classified as prodromal sub-
group showed increased levels of FABP compared to
CON (3.03 vs. 2.87 ng/ml; p < 0.001). Overall,
NMCLRRK2 including the “prodromal subgroup” of
NMCLRRK2 had similar or even lower levels of im-
mune markers compared to CON and thereby did
not present with activated inflammatory profiles as
seen in the PD-affected cohorts.
Discussion
By assessing immune profiles in idiopathic (IPD) and
LRRK2-associated PD patients (PDLRRK2) as well as in yet
non-manifesting LRRK2 mutation carriers (NMCLRRK2)
and healthy control individuals (CON), we show that (1)
levels of inflammatory markers are strongly gender-
dependent, (2) both PD-affected cohorts, stratified by gen-
der, present with increased levels of the pro-inflammatory
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marker FABP, (3) IPD patients, but not PDLRRK2, addition-
ally have increased levels of the pro-inflammatory marker
IL-12-p40 as well as the anti-inflammatory species IL-10,
the neurotrophin BDNF, and the survival factor SCF, and
(4) NMCLRRK2 present with CON-like profiles, arguing
against a relevant role of the inflammatory markers
assessed in this study in the prodromal PDLRRK2 phase.
It is known that several of the markers assessed in this
study show gender-specific differences indicating that im-
mune systems differ substantially between women and
men. While females respond to infection and trauma with
increased antibody production and anti-inflammatory spe-
cies such as IL-4 and IL-10, inflammation itself is usually
more severe in men resulting in increased mortality in
males [23]. In line with the literature and irrespective of the
underlying cohort, females in our study presented with
higher levels of ENA-78, GH, IL-4, IL-12-p40, and leptin
while male participants showed higher levels of IL-1-beta,
IL-6, MMP-3, MMP-9, TF, and TNF-alpha [24–28]. Taking
these gender differences into consideration is of importance
when analyzing immune marker profiles in different co-
horts against disease status.
The finding that both PD-affected cohorts presented
with significantly increased levels of the pro-inflammatory
marker FABP indicates a common disease status-specific
pattern irrespective of the underlying genotype. Proteins
of the FABP family are abundantly expressed in tissue with
fatty acid metabolism such as the brain and the heart. The
main function of FABP is the intracellular transport of
long-chain fatty acids [29]. It was shown that asyn binds
to long-chain fatty acids, resulting in enhanced asyn
oligomerization and Lewy body formation in dopamin-
ergic neurons. FABP overexpression aggravated fatty acid-
induced asyn oligomerization in a mouse model [30]. Al-
though increased serum and/or CSF levels of FABP have
been reported in Lewy body diseases, similar results were
also observed in patients with stroke, brain injury, and
Creutzfeldt-Jakob disease, suggesting that this marker is
rather non-specific [31–33]. Pro-inflammatory IL-12
species including IL-12-p40 are produced by activated
macrophages and microglia and enhance T cell prolifera-
tion and production of other pro-inflammatory cytokines.
IL-12 was previously shown to be increased in serum of
PD patients [34].
Interestingly, we also found anti-inflammatory and
neurotrophic markers to be higher in idiopathic PD pa-
tients than in controls. IL-10 was shown to be neuroprotec-
tive in ischemic cell and animal models and was suggested
to modulate high levels of the pro-inflammatory cytokine
IL-12 in PD patients [34]. BDNF is a widely expressed neu-
rotrophin, which plays a crucial role in neuronal survival.
In inflammatory brain lesions, activated monocytes directly
secrete bioactive BDNF, which promotes neuronal survival
in vitro [13]. Moreover, it was demonstrated that BDNF is
positively associated with inflammatory markers in AD
[35]. Interestingly, increased serum levels of BDNF have
been found in PD patients with longer disease duration and
more severe motor impairment [36]. In vivo and in vitro
experiments show an up-regulation of the stem cell factor
SCF in neurons of injured brain tissue paralleled by neural
stem/progenitor cell migration, indicating that SCF is in-
volved in pathways limiting and/or repairing neuronal dam-
age [37].
All these results indicate that inflammatory processes
are evident in clinically manifest Parkinson’s disease
(potentially to a lesser degree in PDLRRK2 as the median
levels and numbers of inflammatory markers signifi-
cantly different from CON were lower in PDLRRK2 than
in IPD; Table 2, Fig. 1) and are paralleled by increased
Fig. 1 Illustration of the distribution of the discriminant function
scores for IPD, PDLRRK2, and CON stratified by gender. While IPD
patients show little overlap with PDLRRK2 and CON indicating a good
discrimination based on the immune marker profile, PDLRRK2 and
CON present a broader overlap suggesting a possibly less robust
inflammation in PDLRRK2. These findings seem similar across females
and males with an overall discrimination between these three
cohorts of 69.7 % for females and 72.1 % for males
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production of anti-inflammatory and neurotrophic
species, possibly as an attempt to counteract tissue
damage. However, the exact regulatory mechanisms of
pro- and anti-inflammatory pathways need to be further
elucidated.
Neither the whole cohort of NMCLRRK2 nor the sub-
group of “prodromal NMCLRRK2” presented with acti-
vated inflammatory profiles as seen in the PD-affected
cohorts. If we hypothesize that the increased levels of
serum immune markers in the PD cohorts reflect as-
pects of/interaction with the neurodegenerative process,
the findings in NMCLRRK2 suggest that the activation of
the immune system does not start in the very early (pro-
dromal) phase of PDLRRK2 in a relevant proportion of in-
dividuals but rather after clinical diagnosis. However, it
is known that the different prodromal symptoms vary in
their predictive value to PD conversion and that speed
of progression from prodromal to manifest PD varies
among patients and cannot be reliably predicted. There-
fore, our cross-sectional results in the prodromal cohort
need to be interpreted with caution.
Still, we have to keep in mind that most studies in-
cluding ours show a large overlap in levels of immune
markers comparing cohorts of PD patients and healthy
controls. The fact that expression of pro-inflammatory
serum markers differs largely even within the cohorts of
IPD and PDLRRK2 implies that there is a subgroup of in-
dividuals in each group, in which concomitant inflam-
mation may play a major role resulting in individual
pathophysiologic patterns that could be masked when
comparing unselected populations. This needs to be fur-
ther explored as a possible basis for anti-inflammatory
therapeutic strategies. Moreover, the course of neurode-
generation in PD is a dynamic process and most prob-
ably not a linear continuum which makes it difficult to
estimate when inflammatory processes set in and accel-
erate. Furthermore, one has to keep in mind that our
PD-affected cohorts were older than the control group.
Thereby, additional aging-related inflammatory pro-
cesses known as “inflammaging” might contribute to the
inflammatory profiles seen in our PD cohorts.
To overcome limitations of this study, future studies
should specifically address the following aspects: (1) re-
lation of serum markers with, e.g., corresponding cere-
brospinal fluid markers or (post-mortem) brain material
to assess whether these peripheral findings reflect CNS-
specific processes, (2) consideration of potential concomi-
tant immune-related diseases and anti-inflammatory ther-
apies in the participants, (3) longitudinal assessment of
these inflammatory markers, to evaluate the interrelation-
ship of neurodegeneration and (specific) activation of
inflammatory cascades in both IPD and PDLRRK2, (4) lon-
gitudinal assessment in NMCLRRK2 to assess the relation-
ship and time frame between inflammatory markers,
prodromal symptoms, and future development of PD. In
this context, an accurate definition of “prodromal PD”
reflecting a high probability of the individual being in the
phase of ongoing neurodegeneration should be applied.
Conclusions
In conclusion, idiopathic PD patients as well as those
with LRRK2 mutations present with increased levels of
the pro-inflammatory serum markers indicating a com-
mon disease status-specific pattern. These inflammatory
processes are obviously paralleled by anti-inflammatory
and neurotrophic processes, possibly as an attempt to
counteract tissue damage. Non-manifesting LRRK2 mu-
tation carriers with symptoms of the prodromal phase of
PD did not show activated inflammatory profiles as ob-
served in the PD-affected cohorts, suggesting that the
activation of the immune system is not an early event in
the disease cascade in at least the majority of this cohort.
Finally, levels of inflammatory markers show distinct
gender-specific profiles that need to be taken into ac-
count when analyzing immune marker profiles in differ-
ent cohorts against disease status.
Additional files
Additional file 1: Table S1. Overview of frequency of each LRRK2
mutation in the respective cohorts. Table S2. Overview of results from
multivariate linear regression analyses stratified by cohort to illustrate
independent associations between gender, age, disease duration, regular
intake of anti-inflammatory medication, and clinical characteristics with
levels of immune markers. Table S3. Overview of quality control of all
assessed inflammatory markers (analytes). (DOC 224 kb)
Additional file 2: Figure S1. Illustration of the distribution of the
discriminant function scores for gender in the whole cohort of 543
individuals. (TIF 2027 kb)
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